APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide–based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial

BACKGROUND: APF530, a novel extended-release granisetron injection, was superior to ondansetron in a guideline-recommended three-drug regimen in preventing delayed-phase chemotherapy-induced nausea and vomiting (CINV) among patients receiving highly emetogenic chemotherapy (HEC) in the double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnadig, Ian D, Agajanian, Richy, Dakhil, Christopher, Gabrail, Nashat, Vacirca, Jeffrey, Taylor, Charles, Wilks, Sharon, Braun, Eduardo, Mosier, Michael C, Geller, Robert B, Schwartzberg, Lee, Vogelzang, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446958/
https://www.ncbi.nlm.nih.gov/pubmed/28579832
http://dx.doi.org/10.2147/CMAR.S129059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446958/
https://www.ncbi.nlm.nih.gov/pubmed/28579832
http://dx.doi.org/10.2147/CMAR.S129059

Ejemplares similares